Hematology in 10 min: Hemoglobinopathy &Thalassemia

[@misteratoz]

Studying for im boards! Thanks for the refresher.

[@stanleykim1924]

In September 2022, the FDA has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. 89% achieved transfusion independence with Hb > 8 g/dL. Common side effects: mommy comities, neutropenia, thrombocytopenia, anemia.

[@emarupaul7492]

Thanks do much Dr for thy strives to make everything clear

[@bakareolamide4371]

Thank you for this concise presentation

[@josephkaizer2017]

What a great video! A wonderful explanation for a complicated topic. I found this to be extremely helpful while studying for my board exam. Thanks!!

[@somchittanasouralay5016]

1ùķo

[@zoes7026]

Thank you for the brief video!

[@stanleykim1924]

You’re welcome!

[@ravalshreyansh7578]

Wonderful explanation sir I'm an indian

[@sethdjanboakye]

Great Lectures ❤

[@stanleykim1924]

Glad you like them!

[@muhammedsami8912]

Doctor can you explain how to diagnose cases according to CBC and HLPC